XNAS
SRPT
Market cap1.92bUSD
Oct 08, Last price
18.21USD
1D
4.06%
1Q
-3.91%
Jan 2017
-33.61%
Name
Sarepta Therapeutics Inc
Chart & performance
P/E
—
P/S
0.87
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.10%
Rev. gr., 5y
32.41%
Revenues
2.20b
+15.58%
Net income
-713m
L
CFO
-205m
L-0.15%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Key people
Ian Estepan
Chief Financial Officer, Executive Vice President · since 2020
Bilal Arif
Executive Vice President , Chief Technical Operations Officer · since 2022
Dallan Murray
Executive Vice President, Chief Customer Officer · since 2024
Ryan Wong
Chief Financial Officer, Executive Vice President · since 2025
Louise Rodino-Klapac
Executive Vice President, Chief Scientific Officer, Head of R&D · since 2021
Deirdre Connelly
Director · since 2024
Douglas Ingram
President, Chief Executive Officer, Director · since 2017
Richard Barry
Independent Director · since 2015
M. Kathleen Behrens
Independent Chairwoman of the Board · since 2015
Independent Director · since 2022
Michael Chambers
Independent Director · since 2022
Independent Director · since 2021
Independent Director · since 2015
Independent Director · since 2010
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
215 FIRST STREET
SUITE 415
CAMBRIDGE, MA 02142
US
SUITE 415
CAMBRIDGE, MA 02142
US
Previous name
AVI BioPharma (AVII) (SRPT)
Previous name
AVI BioPharma, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||